Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management

Yvette N. Martin, Amy C.S. Pearson, John R. Tranchida, Toby N. Weingarten, Phillip Schulte, Juraj Sprung

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background and objectives Buprenorphine is a partial μ-receptor agonist resistant to displacement from receptors by conventional opioids, which can block the effect of conventional opioids and may interfere with postoperative pain management. We aimed to quantify perioperative opioid use in patients receiving transdermal buprenorphine (TdBUP). Methods We identified patients receiving TdBUP who underwent surgery between 2004 and 2016. To compare opioid requirements (intravenous morphine equivalents (IV-MEq)), we constructed a matched study, matching each TdBUP patient with two opioid-naive patients by sex, age, and type of anesthesia and procedure. Results Nineteen unique patients underwent 22 procedures while receiving TdBUP. Total (IQR) amounts of IV-MEq (intraoperative, recovery room, and 24 hours after recovery-room discharge) were 98 (63, 145) and 46 (30, 65) mg IV-MEq for TdBUP and opioid-naive patients, respectively (p<0.001). Postoperative IV-MEq requirements were 54 (38, 90) and 15 (3, 35) mg for TdBUP and opioid-naive patients, respectively (p<0.001). Among TdBUP patients, higher preoperative doses of TdBUP were associated with greater postoperative opioid requirements (p=0.02). Specifically, patients with a 20 μg/hour TdBUP patch required 133.8 mg IV-MEq more postoperatively than patients with a 5 μg/hour patch (p=0.002). Following discharge from the recovery room, 17 (77%) TdBUP patients and 15 (34%) opioid-naive patients reported severe pain (OR 6.6 (95% CI 2.0 to 21.3); p<0.001; adjusting for baseline pain score, 5.0 (95% CI, 1.4 to 17.8); p=0.01). Conclusions Analgesic management for patients receiving TdBUP therapy must account for increased opioid needs, and greater preoperative doses of TdBUP were associated with greater postoperative opioid requirements.

Original languageEnglish (US)
Pages (from-to)342-347
Number of pages6
JournalRegional Anesthesia and Pain Medicine
Volume44
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Buprenorphine
Pain Management
Postoperative Pain
Opioid Analgesics
Morphine
Recovery Room
Transdermal Patch
Pain
Opioid Receptors
Analgesics

Keywords

  • anesthesia
  • buprenorphine
  • opioid resistance
  • opioids
  • pain
  • surgery
  • transdermal

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management. / Martin, Yvette N.; Pearson, Amy C.S.; Tranchida, John R.; Weingarten, Toby N.; Schulte, Phillip; Sprung, Juraj.

In: Regional Anesthesia and Pain Medicine, Vol. 44, No. 3, 01.03.2019, p. 342-347.

Research output: Contribution to journalArticle

Martin, Yvette N. ; Pearson, Amy C.S. ; Tranchida, John R. ; Weingarten, Toby N. ; Schulte, Phillip ; Sprung, Juraj. / Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management. In: Regional Anesthesia and Pain Medicine. 2019 ; Vol. 44, No. 3. pp. 342-347.
@article{6cb0a9c62ab141b5aec20ad5e0ec0073,
title = "Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management",
abstract = "Background and objectives Buprenorphine is a partial μ-receptor agonist resistant to displacement from receptors by conventional opioids, which can block the effect of conventional opioids and may interfere with postoperative pain management. We aimed to quantify perioperative opioid use in patients receiving transdermal buprenorphine (TdBUP). Methods We identified patients receiving TdBUP who underwent surgery between 2004 and 2016. To compare opioid requirements (intravenous morphine equivalents (IV-MEq)), we constructed a matched study, matching each TdBUP patient with two opioid-naive patients by sex, age, and type of anesthesia and procedure. Results Nineteen unique patients underwent 22 procedures while receiving TdBUP. Total (IQR) amounts of IV-MEq (intraoperative, recovery room, and 24 hours after recovery-room discharge) were 98 (63, 145) and 46 (30, 65) mg IV-MEq for TdBUP and opioid-naive patients, respectively (p<0.001). Postoperative IV-MEq requirements were 54 (38, 90) and 15 (3, 35) mg for TdBUP and opioid-naive patients, respectively (p<0.001). Among TdBUP patients, higher preoperative doses of TdBUP were associated with greater postoperative opioid requirements (p=0.02). Specifically, patients with a 20 μg/hour TdBUP patch required 133.8 mg IV-MEq more postoperatively than patients with a 5 μg/hour patch (p=0.002). Following discharge from the recovery room, 17 (77{\%}) TdBUP patients and 15 (34{\%}) opioid-naive patients reported severe pain (OR 6.6 (95{\%} CI 2.0 to 21.3); p<0.001; adjusting for baseline pain score, 5.0 (95{\%} CI, 1.4 to 17.8); p=0.01). Conclusions Analgesic management for patients receiving TdBUP therapy must account for increased opioid needs, and greater preoperative doses of TdBUP were associated with greater postoperative opioid requirements.",
keywords = "anesthesia, buprenorphine, opioid resistance, opioids, pain, surgery, transdermal",
author = "Martin, {Yvette N.} and Pearson, {Amy C.S.} and Tranchida, {John R.} and Weingarten, {Toby N.} and Phillip Schulte and Juraj Sprung",
year = "2019",
month = "3",
day = "1",
doi = "10.1136/rapm-2018-100018",
language = "English (US)",
volume = "44",
pages = "342--347",
journal = "Regional Anesthesia and Pain Medicine",
issn = "1098-7339",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Implications of uninterrupted preoperative transdermal buprenorphine use on postoperative pain management

AU - Martin, Yvette N.

AU - Pearson, Amy C.S.

AU - Tranchida, John R.

AU - Weingarten, Toby N.

AU - Schulte, Phillip

AU - Sprung, Juraj

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Background and objectives Buprenorphine is a partial μ-receptor agonist resistant to displacement from receptors by conventional opioids, which can block the effect of conventional opioids and may interfere with postoperative pain management. We aimed to quantify perioperative opioid use in patients receiving transdermal buprenorphine (TdBUP). Methods We identified patients receiving TdBUP who underwent surgery between 2004 and 2016. To compare opioid requirements (intravenous morphine equivalents (IV-MEq)), we constructed a matched study, matching each TdBUP patient with two opioid-naive patients by sex, age, and type of anesthesia and procedure. Results Nineteen unique patients underwent 22 procedures while receiving TdBUP. Total (IQR) amounts of IV-MEq (intraoperative, recovery room, and 24 hours after recovery-room discharge) were 98 (63, 145) and 46 (30, 65) mg IV-MEq for TdBUP and opioid-naive patients, respectively (p<0.001). Postoperative IV-MEq requirements were 54 (38, 90) and 15 (3, 35) mg for TdBUP and opioid-naive patients, respectively (p<0.001). Among TdBUP patients, higher preoperative doses of TdBUP were associated with greater postoperative opioid requirements (p=0.02). Specifically, patients with a 20 μg/hour TdBUP patch required 133.8 mg IV-MEq more postoperatively than patients with a 5 μg/hour patch (p=0.002). Following discharge from the recovery room, 17 (77%) TdBUP patients and 15 (34%) opioid-naive patients reported severe pain (OR 6.6 (95% CI 2.0 to 21.3); p<0.001; adjusting for baseline pain score, 5.0 (95% CI, 1.4 to 17.8); p=0.01). Conclusions Analgesic management for patients receiving TdBUP therapy must account for increased opioid needs, and greater preoperative doses of TdBUP were associated with greater postoperative opioid requirements.

AB - Background and objectives Buprenorphine is a partial μ-receptor agonist resistant to displacement from receptors by conventional opioids, which can block the effect of conventional opioids and may interfere with postoperative pain management. We aimed to quantify perioperative opioid use in patients receiving transdermal buprenorphine (TdBUP). Methods We identified patients receiving TdBUP who underwent surgery between 2004 and 2016. To compare opioid requirements (intravenous morphine equivalents (IV-MEq)), we constructed a matched study, matching each TdBUP patient with two opioid-naive patients by sex, age, and type of anesthesia and procedure. Results Nineteen unique patients underwent 22 procedures while receiving TdBUP. Total (IQR) amounts of IV-MEq (intraoperative, recovery room, and 24 hours after recovery-room discharge) were 98 (63, 145) and 46 (30, 65) mg IV-MEq for TdBUP and opioid-naive patients, respectively (p<0.001). Postoperative IV-MEq requirements were 54 (38, 90) and 15 (3, 35) mg for TdBUP and opioid-naive patients, respectively (p<0.001). Among TdBUP patients, higher preoperative doses of TdBUP were associated with greater postoperative opioid requirements (p=0.02). Specifically, patients with a 20 μg/hour TdBUP patch required 133.8 mg IV-MEq more postoperatively than patients with a 5 μg/hour patch (p=0.002). Following discharge from the recovery room, 17 (77%) TdBUP patients and 15 (34%) opioid-naive patients reported severe pain (OR 6.6 (95% CI 2.0 to 21.3); p<0.001; adjusting for baseline pain score, 5.0 (95% CI, 1.4 to 17.8); p=0.01). Conclusions Analgesic management for patients receiving TdBUP therapy must account for increased opioid needs, and greater preoperative doses of TdBUP were associated with greater postoperative opioid requirements.

KW - anesthesia

KW - buprenorphine

KW - opioid resistance

KW - opioids

KW - pain

KW - surgery

KW - transdermal

UR - http://www.scopus.com/inward/record.url?scp=85067823544&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067823544&partnerID=8YFLogxK

U2 - 10.1136/rapm-2018-100018

DO - 10.1136/rapm-2018-100018

M3 - Article

AN - SCOPUS:85067823544

VL - 44

SP - 342

EP - 347

JO - Regional Anesthesia and Pain Medicine

JF - Regional Anesthesia and Pain Medicine

SN - 1098-7339

IS - 3

ER -